Renalytix AI prepares for US roll-out with CPT code

Artificial intelligence-based kidney disease clinical diagnostics developer Renalytix AI announced on Monday that the American Medical Association (AMA) has granted a ‘CPT Proprietary Laboratory Analyses’ (PLA) code for its lead product, ‘KidneyIntelX’.

The AIM-traded firm said the new code, 0105U, had been approved and published by the AMA CPT editorial panel, and was scheduled to become effective on 1 October.

A payment rate for the new code would be established for Medicare patients through the 2019 Clinical Lab Fee Schedule (CLFS) annual public meeting process.

Renayltix AI said it would shortly provide comments and a recommendation on the appropriate basis for establishing a national Medicare price for the new CPT code, expected to be effective 1 January.

“This is an important step as we prepare for KidneyIntelX's scaled roll-out in the United States,” said Renalytix chief medical officer Michael Donovan.

“A CPT Code is instrumental in obtaining insurance coverage and reimbursement, and will increase access to KidneyIntelX testing results for patients with chronic kidney disease.”